Editas Medicine Inc expected to post a loss of 54 cents a share - Earnings Preview

Editas Medicine

16/02/2024 14:14

* Editas Medicine Inc  EDIT.OQ   EDIT.O  is expected to show
a
rise in quarterly revenue when it reports  results on February
20 (estimated) for the period ending December 31 2023
    * The Cambridge Massachusetts-based  company is expected to
report
a 21.5% increase in revenue to $7.943 million from $6.54 million
a year ago, according to the mean estimate from 12 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Editas Medicine Inc is
for a
loss of 54 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 9
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Editas
Medicine
Inc is $15.00​, above​ its last closing price of $8.31. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.56       -0.57      -0.55     Beat    3.2
 Jun. 30 2023  -0.76       -0.76      -0.56     Beat    26.6
 Mar. 31 2023  -0.78       -0.78      -0.71     Beat    9.4​
 Dec. 31 2022  -0.80       -0.80      -0.88     Missed  -9.7
 ​​Sep.        -0.83       -0.87      -0.81     Beat    6.8
 30 2022                                                
 Jun. 30 2022  -0.81       -0.82      -0.78     Beat    5.1​
 Mar. 31 2022  -0.78       -0.80      -0.74     Beat    6.9
 Dec. 31 2021  -0.68       -0.72      -0.61     Beat    15.4
 This summary was machine generated February 16 at 14:14 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)